Cancer Supportive Care Drugs Market (By Therapeutic Class: G-CSFs, Anti-emetics, ESAs, Bisphosphonates, Opioids, NSAIDs & Others)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

The global cancer supportive care drugs market was valued at USD 14.13 billion in 2021 and it is predicted to surpass around USD 12.37 billion by 2030 with a CAGR of -1.47% from 2022 to 2030.

This decline is due to factors, such as the launch of biosimilar and approval & uptake of targeted treatments for cancer, which have lesser side effects than traditional chemotherapy drugs. The growing cancer prevalence, high adoption & dependency on traditional treatments, such as chemotherapy, in the developing region, and the rising geriatric population are some of the prominent factors that drive the market growth. According to Globocan, the number of new cancer cases is expected to reach 28.4 million within the next two decades, with a rise of 47% from 2020.

In addition, in developing regions, such as Asian and African countries, due to less disposable income levels and lack of proper reimbursement scenarios, chemotherapy is the most widely preferred cancer treatment compared to other costly targeted therapies. However, the growing adoption of targeted therapies and biosimilars in Europe and the U.S. impedes the market growth. The patent expiration of blockbuster drugs, such as Amgen Inc.’s Neupogen and Neulasta and Johnson & Johnson Services, Inc.’s Procrit/Eprex, is another factor that hampers the market growth. Furthermore, the COVID-19 pandemic has had a significant impact on cancer care. There was a substantial decline in hospital visits, cancer screenings, surgeries, and therapy amid the pandemic.

However, the impact of the pandemic has declined and conditions are getting back to normal in many regions from the second quarter of 2021. Key players are addressing the opportunity of drug patient expiration and thus, are launching biosimilars in the market. The launch of biosimilars has supported expanded access to affordable care for cancer patients. For instance, in June 2020, Pfizer Inc. received the U.S. FDA approval for NYVEPRIA (pegfilgrastim-apgf), a biosimilar to Neulasta. It reduces the incidence of febrile neutropenia in patients with non-myeloid malignancies undergoing myelosuppressive anticancer medications. In November 2019, Novartis AG received the FDA approval for Ziextenzo, its biosimilar version of pegfilgrastim. The product was commercialized in Europe in 2018.

Scope of The Report

Report Coverage Details
Market Size in 2021 USD 14.13 billion
Revenue Forecast by 2030 USD 12.37 billion
Growth rate from 2022 to 2030 CAGR of -1.47%
Base Year 2021
Forecast Period 2022 to 2030
Segmentation Phase, study design, therapeutic areas, region
Companies Covered Amgen, Inc; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Heron Therapeutics, Inc.; Novartis AG; GlaxoSmithKline plc (GSK); F. Hoffmann-La Roche Ltd.; Helsinn Healthcare SA


Therapeutic Class Insights

The Granulocyte Colony Stimulating Factor (G-CSF) segment held the largest revenue share of more than 26.00% in 2021. It is a primary treatment option for cancer-related neutropenia. It is among the most commonly used supportive care drugs for breast and lymphoma cancers. For instance, G-CSF is administered to 70% of breast cancer and 84% of lymphoma patients in the U.K. However, the rising use of Immuno-Oncology (IO) agents, such as anti-PD-1/L1s, in treatment results in the decline of myelosuppressive chemotherapy, which restricts the growth of G-CSF. The antiemetics segment is expected to show positive growth during the forecast period.

Chemotherapy-induced Nausea & Vomiting (CINV) is among the most common problems faced by patients on chemotherapy. The positive growth is due to the launch of newer drugs, such as Cinvanti, Sustol, and Varubi. However, the patent expiry of key antiemetic drugs, such as Emend, will impact the overall CINV drugs revenue. The opioid segment growth is expected to decline during the forecast period. Governments in several countries, including the U.S. government, have been imposing stringent regulations on opioid drugs. Due to this, the prescription rate for opioid drugs has declined drastically. For instance, according to the National Cancer Institute, between 2013 and 2017, the national opioid prescription rate declined by around 21% among oncologists. Thus, such factors are anticipated to impede the growth of opioid drugs over the forecast period.

Regional Insights

Based on geographies, the global market has been further divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America and other developed regions is expected to decline over the forecast period on account of the launch and rapid uptake of biosimilar and restrictions on opioid prescription. In addition, these regions have high adoption of personalized, targeted therapies as a result of their fewer side effects along with the increased awareness about the availability of such therapies and favorable reimbursement policies for high-cost targeted therapies. The developing regions, such as Asia Pacific, Latin America, and the Middle East & Africa, have high unmet needs for cancer supportive care. On account of the less developed healthcare systems and low disposable income levels in these regions, chemotherapy is still predominantly used as treatment. These factors are expected to drive market growth in these regions.

Key Players

  • Amgen, Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Heron Therapeutics, Inc.
  • Novartis AG
  • GlaxoSmithKline plc (GSK)
  • F. Hoffmann-La Roche Ltd.
  • Helsinn Healthcare SA

Market Segmentation

By Therapeutic Class Outlook

  • G-CSFs (Granulocyte-colony Stimulating Factors)
  • ESAs (Erythropoiesis Stimulating Agents)
  • Anti-emetics
  • Bisphosphonates
  • Opioids
  • NSAIDs & Others

By Regional Outlook

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • Germany
    • Spain
    • France
    • Italy
    • Russia
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
  • Latin America
    • Brazil
  • Middle East & Africa
    • South Africa

Report Detail

Proceed To Buy

USD 3500
USD 7000